Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression

被引：18
作者：
Li, Li [1 ]
Nan, Fangfang [1 ]
Guo, Qingzhi [1 ]
Guan, Dongdong [1 ]
Zhou, Chao [1 ]
机构：
[1] Binzhou Med Univ Hosp, Dept Obstet & Gynecol, Binzhou 256603, Shandong, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2019年 / 15卷 / 06期
关键词：
Bevacizumab; EphB4; ovarian cancer cells; xenograft; CELLS; INHIBITOR; THERAPY;
D O I：
10.4103/0973-1482.204896
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim of Study: Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined.Materials and Methods: In this study, we used ovarian xenograft model to evaluate the underlying resistance mechanisms of BV in ovarian cancer treatment.Results: Our results showed that EphB4 was overexpressed in BV-resistant xenograft models instead of other common receptor tyrosine kinases. In addition, when coadministrated with EphB4 blocker NVP-BHG712, the antitumor effect of BV was significantly enhanced in the resistant model, further confirmed the role of EphB4 in BV-resistant ovarian cancer. These results indicate that NVP-BHG712 reverses EphB4 overexpression-mediated resistance to BV.Conclusion: These findings represent a guide for the design of future medication strategy and may be useful in guiding the use of BV in combination with NVP-BHG712 in patients with resistance or intolerance ovarian cancer.
引用
收藏
页码：1282 / 1287
页数：6
相关论文
共 19 条
[1]   The biology of ovarian cancer: new opportunities for translation [J].
Bast, Robert C., Jr. ;
Hennessy, Bryan ;
Mills, Gordon B. .
NATURE REVIEWS CANCER, 2009, 9 (06) :415-428
[2]   TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer [J].
Deng, Zhuo ;
Zhou, Jiancheng ;
Han, Xi ;
Li, Xu .
ONCOLOGY REPORTS, 2016, 35 (01) :359-365
[3]   Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity [J].
Gottschalk, Nina ;
Kimmig, Rainer ;
Lang, Stephan ;
Singh, Mahavir ;
Brandau, Sven .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (09) :12000-12016
[4]   Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer [J].
Guerrouahen, Bella S. ;
Pasquier, Jennifer ;
Abu Kaoud, Nadine ;
Maleki, Mahtab ;
Beauchamp, Marie-Claude ;
Yasmeen, Amber ;
Ghiabi, Pegah ;
Lis, Raphael ;
Vidal, Fabien ;
Saleh, Ahmed ;
Gotlieb, Walter H. ;
Rafii, Shahin ;
Rafii, Arash .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) :3123-3136
[5]   Clinical trials and future potential of targeted therapy for ovarian cancer [J].
Itamochi, Hiroaki ;
Kigawa, Junzo .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (05) :430-440
[6]   The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study [J].
Kathawala, Rishil J. ;
Wei, Liuya ;
Anreddy, Nagaraju ;
Chen, Kang ;
Patel, Atish ;
Alqahtani, Saeed ;
Zhang, Yun-Kai ;
Wang, Yi-Jun ;
Sodani, Kamlesh ;
Kaddoumi, Amal ;
Ashby, Charles R., Jr. ;
Chen, Zhe-Sheng .
ONCOTARGET, 2015, 6 (01) :510-521
[7]   The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome [J].
Kumar, S. R. ;
Masood, R. ;
Spannuth, W. A. ;
Singh, J. ;
Scehnet, J. ;
Kleiber, G. ;
Jennings, N. ;
Deavers, M. ;
Krasnoperov, V. ;
Dubeau, L. ;
Weaver, F. A. ;
Sood, A. K. ;
Gill, P. S. .
BRITISH JOURNAL OF CANCER, 2007, 96 (07) :1083-1091
[8]   The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis [J].
Li, Jun ;
Li, Shufen ;
Chen, Ruifang ;
Yu, Hailin ;
Lu, Xin .
JOURNAL OF OVARIAN RESEARCH, 2015, 8
[9]   Suppression of EphB4 Improves the Inhibitory Effect of mTOR shRNA on the Biological Behaviors of Ovarian Cancer Cells by Down-regulating Akt Phosphorylation [J].
Ma, Xiangyi ;
Luo, Danfeng ;
Li, Kezhen ;
Liu, Ronghua ;
Liu, Yan ;
Zhu, Tao ;
Deng, Dongrui ;
Zhou, Jianfeng ;
Meng, Li ;
Wang, Shixuan ;
Ma, Ding .
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2012, 32 (03) :358-363
[10]   Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer [J].
Mahner, Sven ;
Woelber, Linn ;
Mueller, Volkmar ;
Witzel, Isabell ;
Prieske, Katharina ;
Grimm, Donata ;
Amsberg, Gunhild Keller-v ;
Trillsch, Fabian .
FRONTIERS IN ONCOLOGY, 2015, 5
12